178452
Apolipoprotein A-I, Human Plasma, High-Density Lipoprotein
Native apolipoprotein A-I from human plasma. Functions as a cofactor for lecithin-cholesterol acyltransferase. A component of high density lipoprotein.
Synonyme(s) :
Apo A-I
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352202
Nomenclature NACRES :
NA.25
Produits recommandés
Niveau de qualité
Pureté
≥95% (SDS-PAGE)
Forme
liquid
Fabricant/nom de marque
Calbiochem®
Conditions de stockage
OK to freeze
avoid repeated freeze/thaw cycles
Conditions d'expédition
wet ice
Température de stockage
−20°C
Description générale
Functions as a cofactor of lecithin cholesterol acyltransferase (LCAT).
Native apolipoprotein A-I from human plasma. Functions as a cofactor for lecithin-cholesterol acyltransferase (LCAT). Plays an important role in HDL metabolism.
Conditionnement
Please refer to vial label for lot-specific concentration.
Avertissement
Toxicity: Standard Handling (A)
Forme physique
In 10 mM NH₄HCO₃, pH 7.4.
Notes préparatoires
Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C). Store at a concentration ≥1 mg/ml.
Autres remarques
Bergot, C., et al. 2001. Eur. J. Biochem.268, 3523.
Pászty, C., et al. 1994. J. Clin. Invest.94, 899.
Breslow, J.L. 1993. Proc. Natl. Acad. Sci. USA90, 8314.
Schultz, J.R., et al. 1992. J. Biol. Chem.267, 21630.
Walsh, A., et al. 1989. J. Biol. Chem.264, 6488.
Brewer, H.B. 1986. Methods Enzymol. 128, 223.
Pászty, C., et al. 1994. J. Clin. Invest.94, 899.
Breslow, J.L. 1993. Proc. Natl. Acad. Sci. USA90, 8314.
Schultz, J.R., et al. 1992. J. Biol. Chem.267, 21630.
Walsh, A., et al. 1989. J. Biol. Chem.264, 6488.
Brewer, H.B. 1986. Methods Enzymol. 128, 223.
Informations légales
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Ce produit, destiné à la recherche scientifique, est soumis à une réglementation spécifique en France, y compris pour les activités d′importation et d′exportation (Article L 1211-1 alinéa 2 du Code de la Santé Publique). L′acheteur (c′est-à-dire l′utilisateur FINAL) est tenu d′obtenir une autorisation d′importation auprès du ministère français de la recherche, mentionné à l′article L1245-5-1 II du Code de la Santé Publique. En commandant ce produit, vous confirmez détenir l′autorisation d′importation requise.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 1
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Mengxi Wang et al.
Oxidative medicine and cellular longevity, 2022, 2226168-2226168 (2022-12-16)
At present, due to the limitations of drug therapy targets for atherosclerosis, some patients fail to achieve satisfactory efficacy. Cholesterol efflux dysfunction and endothelial cell inflammation are considered to be important factors in the development of atherosclerosis. Peroxisome proliferator-activated receptor
Remco Franssen et al.
Cholesterol, 2012, 610741-610741 (2012-05-23)
HDL provides atheroprotection by facilitating cholesterol efflex from lipid-laden macrophages in the vessel wall. In vitro studies have suggested impaired efflux capacity of HDL following inflammatory changes. We assessed the impact of acute severe sepsis and mild chronic inflammatory disease
Sanne J C M Frambach et al.
Life sciences, 300, 120571-120571 (2022-04-27)
Mitochondrial complex I (CI), the first multiprotein enzyme complex of the oxidative phosphorylation system, plays a crucial role in cellular energy production. CI deficiency is associated with a variety of clinical phenotypes, including Leigh syndrome. At the cellular level, an
Sylwia Wasiak et al.
Data in brief, 8, 1280-1288 (2016-08-30)
Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on histone tails. Data presented here supports the manuscript published in Atherosclerosis "RVX-208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL
Dean Gilham et al.
Atherosclerosis, 247, 48-57 (2016-02-13)
High density lipoproteins (HDL), through activity of the main protein component apolipoprotein A-I (ApoA-I), can reduce the risk of cardiovascular disease (CVD) by removing excess cholesterol from atherosclerotic plaque. In this study, we demonstrate that the bromodomain and extraterminal domain
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique